You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. High Resolution Fluorescent Melting Curve Analysis

    SBC: IDAHO TECHNOLOGY            Topic: N/A

    DESCRIPTION (Applicant's abstract): Our long-term goal is to advance instrumentation and techniques for rapid, automated and sensitive variant analysis of nucleic acids. The LightCyclerTM has been our homogenous "closed system" platform for genotyping. Fluorescent hybridization probes are included at the beginning of the reaction and are used for realtime P ...

    STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health
  2. Retroviral Vectors for Cancer Gene Therapy

    SBC: INTRAGENE SCIENCES, INC.            Topic: N/A

    Many strategies for gene therapy of solid tumors such as prostate cancer have involved the use of Moloney murine leukemia (MLV)-based retroviral vectors, but gene transfer with standard replication-defective MLV vectors has not been efficient due to their low titers and limited diffusion into the tumor. Gene transfer using replication-competent retroviral vectors would be more efficient, as each ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  3. NOVEL ANTI-PAIN MEDICATIONS FOR CANCER

    SBC: IRISYS RESEARCH AND DEVELOPMENT            Topic: N/A

    DESCRIPTION (provided by applicant): The chemical synthesis and biological evaluation of novel, highly potent agents for the treatment of both severe acute and chronic pain associated with cancer and other diseases that has minimal side effects such as addiction liability, imniunosuppression and respiratory depression is very urgent. For "proof of princip ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  4. Identification of a Neuronal Immunosuppressive Protein

    SBC: LAYTON BIOSCIENCE, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Development of Ntera2/D1 neurons as an alternative to embryonic neurons for transplantation therapy to ameliorate neurological deficits, currently in a Phase I trial for stroke symptoms, led to our discovery of a 40-60 kDA anionic protein with an isoelectric point of 4.8 expressed by these neurons that inhibits T-lymphocyte activa ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  5. AIRWAY PERFUSION ASSISTED LIQUID VENTILATOR

    SBC: MALLARD MEDICAL CO., INC.            Topic: N/A

    DESCRIPTION (provided by applicant): We have developed and patented (U.S. Pat No. 5,706,830) a new type of closed circuit perfluorocarbon (PFC) liquid ventilator with enhanced capabilities for gas exchange and exudates clearance from the lungs. This system has potential application to rescue of patients in acute respiratory failure and treatment of cystic fibrosis. ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  6. AIRWAY PERFUSION ASSISTED LIQUID VENTILATOR

    SBC: MALLARD MEDICAL CO., INC.            Topic: N/A

    DESCRIPTION (provided by applicant): We have developed and patented (U.S. Pat No. 5,706,830) a new type of closed circuit perfluorocarbon (PFC) liquid ventilator with enhanced capabilities for gas exchange and exudates clearance from the lungs. This system has potential application to rescue of patients in acute respiratory failure and treatment of cystic fibrosis. ...

    STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Standardized Milk Thistle Product

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (Provided by applicant): The objective of this Phase I and II fast track application is to develop a standardized milk thistle product and to assure a quality controlled and reliable source for future basic and clinical studies. Natural Pharmacia International, Inc, an established natural products laboratory, has established an excellent consortial team to establish a standardized milk ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Standardized Milk Thistle Product

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (Provided by applicant): The objective of this Phase I and II fast track application is to develop a standardized milk thistle product and to assure a quality controlled and reliable source for future basic and clinical studies. Natural Pharmacia International, Inc, an established natural products laboratory, has established an excellent consortial team to establish a standardized milk ...

    STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health
  9. PET Reagents for Normal and Tumor Tissue Hypoxia

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Disruption of O2 gradients in normal tissues creates major medical problems including cardiovascular disease, stroke, diabetes, liver and kidney damage and organ transplant failure. Steep O2 gradients in tumors protect tumor cells from cytotoxic therapies and create more aggressive tumors. Measurements of O2 gradients are cle ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  10. Molecular Markers for Tissue Hypoxia

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (PROVIDED BY APPLICANT): Hypoxia is important in cardiovascular disease and cancer, the two leading causes of death in the US. Studies of these and other diseases need a tool for following changes in tissue hypoxia. We propose the HypoxyprobeTM system of markers can meet this need. HypoxyprobeTM markers have advantages of high water solubility, chemical s ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government